Drug Profile
Research programme: casein kinase II inhibitors - Polaris Pharmaceuticals
Alternative Names: CK2 alpha inhibitors - Polaris; PX-228Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Phoenix Pharmacologics
- Developer Polaris Pharmaceuticals
- Class Small molecules
- Mechanism of Action Casein kinase II inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
- 26 May 2010 Preclinical development is ongoing USA